Plasmodium parasites cause malaria morbidity and mortality in over 40% of the worlds population. Despite a complex parasite life cycle, immunization with irradiated sporozoites can elicit sterile immunity in mice, monkeys and humans, providing a gold standard for a pre-erythrocytic stage malaria vaccine. Since sporozoites cannot be produced in vitro, efforts have focused on developing subunit vaccines that elicit immune responses comparable to irradiated sporozoites. Over the past grant period, we have shown that synthetic peptides and hepatitis B virus core protein virus-like particles (VLP) containing minimal P. falciparum CS protein epitopes, were safe and immunogenic in preclinical and Phase I trials. In the current grant, the fine specificity and function of antibody and cells elicited in volunteers immunized with ICC-1132, a VLP expressing P. falciparum CS repeats and the universal T* Th epitope, will be examined (Specific Aim 1). The protective efficacy of this VLP and linear peptide vaccines will be compared and the immune mechanisms of protection defined using transgenic parasites expressing P. falciparum CS epitopes (Specific Aim 2). In an effort to optimize humoral and cellular responses, truncated T and B cell epitopes will be tested as peptide vaccines (Specific Aim 2) and heterologous prime:boost immunization strategies, using VLP and peptides, will be assayed for protective efficacy (Specific Aim 3). A major limitation in P. falciparum vaccine Phase II trials is the inability to dissect immune responses of human volunteers to define correlates of protective immunity. We will therefore construct P. berghei transgenics expressing P. falciparum CS major or minor repeats, or the universal T* epitope, to establish small animal models for analysis of protective immune mechanisms elicited by P. falciparum CS subunit vaccines (Specific Aim 4). The information gained from these studies will be applicable to development of vaccines against malaria blood stage parasites, as well as viral and bacterial pathogens that require strong humoral responses for protective immunity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI045138-05A2
Application #
6985967
Study Section
Special Emphasis Panel (ZRG1-VMD (01))
Program Officer
MO, Annie X Y
Project Start
1999-09-15
Project End
2010-03-31
Budget Start
2005-07-08
Budget End
2006-03-31
Support Year
5
Fiscal Year
2005
Total Cost
$438,138
Indirect Cost
Name
New York University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Przysiecki, Craig; Lucas, Bob; Mitchell, Robert et al. (2012) Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex. Front Cell Infect Microbiol 2:146
Frevert, Ute; Moreno, Alberto; Calvo-Calle, J Mauricio et al. (2009) Imaging effector functions of human cytotoxic CD4+ T cells specific for Plasmodium falciparum circumsporozoite protein. Int J Parasitol 39:119-32
Othoro, Caroline; Johnston, Dean; Lee, Rebecca et al. (2009) Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect Immun 77:739-48
Frevert, Ute; Nardin, Elizabeth (2008) Cellular effector mechanisms against Plasmodium liver stages. Cell Microbiol 10:1956-67
Calvo-Calle, J Mauricio; Oliveira, Giane A; Watta, Carol Othoro et al. (2006) A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge. Infect Immun 74:6929-39
Oliveira, Giane A; Wetzel, Kristiane; Calvo-Calle, J Mauricio et al. (2005) Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 73:3587-97
Calvo-Calle, Jaime Mauricio; Oliveira, Giane A; Nardin, Elizabeth H (2005) Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites. J Immunol 175:7575-85
Nardin, Elizabeth H; Oliveira, Giane A; Calvo-Calle, J Mauricio et al. (2004) Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 72:6519-27
Persson, Cathrine; Oliveira, Giane A; Sultan, Ali A et al. (2002) Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 169:6681-5
Nardin, E H; Calvo-Calle, J M; Oliveira, G A et al. (2001) A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 166:481-9